Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

HIV Infections Clinical Trials

A listing of HIV Infections medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (19) clinical trials

Safety Tolerability DDI Short Course Treatment of LTBI Infection With High-dose Rifapentine Isoniazid in HIV+ Patients

Single-arm, single-center, Phase I/II clinical trial, in two Groups. Individuals with HIV infection taking EFV and two nucleoside reverse transcriptase inhibitors (NRTI) who have undetectable HIV viral load and an indication for treatment of LTBI, will be switched to DTG with tenofovir/emtricitabine for at least two months and will receive ...

Phase

Safety and Immunogenicity of Clade C ALVAC and gp120 HIV Vaccine

This study will evaluate the safety, tolerability, and immunogenicity to vCP2438 (an HIV clade C vaccine) and to an unadjuvanted or MF59- or alum-adjuvanted bivalent clade C gp120 in healthy, HIV-uninfected adults. The study will enroll healthy, HIV-uninfected participants aged 18 to 40 years. Participants will be randomly assigned to ...

Phase

Soy Modulation of Immune Activation LDL- Levels and Lowering Inflammation by Pretzel Isoflavone Dietary Intervention

This study will significantly advance our knowledge of how dietary soy impacts lipid levels and composition, metabolic parameters and inflammation in HIV+ patients treated with anti-retroviral therapy (ART). HIV+ persons are at increased risk for CVD, and both HIV and ART are associated with metabolic perturbations (including lipid disturbances) and ...

Phase

Attenuation of D-dimer Using Vorapaxar to Target Inflammatory and Coagulation Endpoints

Consenting participants will be screened and within 14 days randomly allocated to receive either vorapaxar (2.5mg) or matched placebo once daily for 12 weeks (phase 1). Participants will be seen one week after randomisation and then at weeks 4, 8 and 12 (phase 1). At the week 12 visit, patients ...

Phase

Safety and Efficacy of Allogenic Adoptive Immune Therpy for Immune Reconstitution in Chronic HIV-1 Infected Patients

There is not a consensus definition of immunologic nonresponder individuals. In this study, we described patients whose CD4+ T-cell count remained below 200 cells/ul after 2 years of effective antiviral as immunologic nonresponders, in which viroimmunologic dissociation implies a greater risk of AIDS related and non-AIDS-related illnesses. Immune-based therapy such ...

Phase

Depletion of Serum Amyloid P Component to Enhance the Immune Response to DNA Vaccination

Vaccination is one of the most important achievements of medicine. Injection of modified germs, or materials from them, induces protective immunity against the infections which they cause. Successful immunisation induces a protective immune response against particular component(s) of the target germ, the so-called immunogen(s). For some diseases the immunogens are ...

Phase

Reducing the Residual Reservoir of HIV-1 Infected Cells in Patients Receiving Antiretroviral Therapy

This study is a prospective, triple-arm, randomized, open-label, dose-escalation exploratory clinical trial involving HIV-1 infected participants treated with suppressive combination antiretroviral combination therapy (cART). The primary objective of this study is to evaluate a new strategy for reducing the residual reservoir of HIV-1 infected cells that persists despite treatment with ...

Phase

The Effect of Ixazomib on the Latent HIV Reservoir

The goal of this study is to determine the safety and tolerability of Ixazomib in HIV infected patients who are on a stable regimen of ART that suppresses HIV replication. A secondary goal is to determine the effect of ixazomib on the size of the HIV reservoir.

Phase

Evaluating the Pharmacokinetics Safety and Tolerability of Bedaquiline in HIV-Infected and HIV-Uninfected Infants Children and Adolescents With Multidrug-Resistant Tuberculosis

This purpose of this study is to evaluate the pharmacokinetics (PK), safety, and tolerability of bedaquiline (BDQ) in combination with an optimized background multidrug-resistant tuberculosis (MDR-TB) treatment regimen in HIV-infected and HIV-uninfected infants, children, and adolescents. The study will enroll HIV-infected and HIV-uninfected children 0 to 18 years of age ...

Phase

Evaluating the Pharmacokinetics Safety and Tolerability of Doravirine (MK-1439) and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (MK-1439A) in HIV-1-Infected Children and Adolescents

This study will evaluate the pharmacokinetics (PK), safety, and tolerability of DOR and DOR/3TC/TDF in HIV-1-infected children and adolescents. This study will be conducted in two sequential cohorts: Cohort 1 and Cohort 2. At study entry (Day 0), participants in Cohort 1 will receive a single dose of DOR added ...

Phase